Preferences for attributes of oral antipsychotic treatments: results from a discrete-choice experiment in respondents with schizophrenia or bipolar I disorder
In this DCE, treatment efficacy was the most important attribute of oral antipsychotic medications among respondents with SZ and BD-I. Weight gain and sexual dysfunction were the adverse effects respondents most wanted to avoid; however, both cohorts were willing to accept some weight gain or sedation to obtain better efficacy. These results highlight features that patients value in antipsychotic medications and how they balance benefits and risks when choosing among treatments.
Authors
- Leslie Citrome (ORCID: https://orcid.org/0000-0002-6098-9266)
- Marco Boeri (ORCID: https://orcid.org/0000-0001-7346-2132)
- Michael J. Doane (ORCID: https://orcid.org/0009-0006-6102-2459)
- Cooper Bussberg (ORCID: https://orcid.org/0000-0002-7854-3596)
- Caroline Vass (ORCID: https://orcid.org/0000-0002-6385-2812)
- Martha Sajatovic (ORCID: https://orcid.org/0000-0002-3073-668X)
- H. Panchmatia
Institutions
- Queen's University Belfast (GB)
- New York Medical College (US)
- University Hospitals of Cleveland (US)
- University of Manchester (GB)
- Alkermes (United States) (US)
- RTI Health Solutions (US)
- University School (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- BMC Psychiatry
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1186/s12888-024-06034-1
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Teva Pharmaceutical Industries
- Johns Hopkins University
- H. Lundbeck A/S
- Epilepsy Society
- National Institutes of Health
- Centers for Disease Control and Prevention